http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진혜경(Hea Kyung Jhin),신지용(Jee yong Shin) 한국중독정신의학회 1999 중독정신의학 Vol.3 No.1
Adolescent substance abuse is a heterogenous phenomenon in context of encompassing diverse substances patterns, and etiologies. Recently there has been a remarkable resurgence in adolescent substance abuse in Korea. Eevn if majority of adolescents who use substances do not progress to abuse or dependence, earlier adolescent substances use and heavier adolescent substance use are strongly related with greater risk of later drug problems. The etiology of adolescent substance abuse is not involved with a single factor, but multiple etiological pathways including biological factors(genetic, temperament), developmental factors, psychological factors, familial factors, social factor, sexual factors, and individual characteristics. There is no single resilence trait, and risk factors interact with protective factors including intelligence, problem-solving ability, positive self-esteem, supportive family relationships, and affect reglulation. The author will review the adolescent substance abuse focusing on multifactorial etiological pathways in terms of developmental view point of adolescence.
품행장애 청소년과 정상 청소년의 자아방어기제에 관한 비교 연구
송재호(Jae-Ho Song),진혜경(Hea-Kyung Jhin),김봉석(Bongseog Kim) 대한소아청소년정신의학회 2009 소아청소년정신의학 Vol.20 No.3
Objectives:This study explored the differences in their ego defense mechanisms between adolescents with conduct disorder and normal adolescents. Methods:Subjects were 35 adolescents with conduct disorder and 44 normal adolescents. The Ewha Defense Mechanism Test (EDMT), consisting of 200 items and 20 scales, was administered, to examine the defense mechanisms of both groups of adolescents. Results:Normal adolescents presented statistically significantly higher scores on the reaction formation, controlling, suppression, anticipation, dissociation, and distortion scales than did adolescents with conduct disorder. Zn addition, adolescents with conduct disorder used neurotic defense mechanisms of both neurotic and mature levels less frequently than normal adolescents did. Factor analysis revealed that, normal adolescents had higher scores on ego-expansive factor scales and behavior control factor scales thanadolescents with conduct disorder did. Conclusion:The results suggest adolescents with conduct disorder use mature and ego-expansive defense mechanisms less frequently than do normal adolescents.
소아청소년 자폐 스펙트럼장애에서 메칠페니데이트 사용의 임상적 특징에 대한 후향적 분석
박진박(Jin-Park Park),이종일(Jong-Il Lee),진혜경(Hea-Kyung Jhin),민혜지(Hae-Ji Min),황준원(Jun-Won Hwang),김예니(Yeni Kim) 대한소아청소년정신의학회 2012 소아청소년정신의학 Vol.23 No.3
Objectives:The purpose of this study was to investigate clinical characteristics of children and adolescents with autism spectrum disorders (ASDs) using methylphenidate (MPH). Methods:Retrospective review of the charts of 79 children and adolescents with ASDs, who visited the Department of Child and Adolescent Psychiatry of Seoul National Hospital, from July 2010 to July 2011, was conducted. Changes in illness severity and improvement were measured using the Clinical Global Impression-Severity of illness (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scales. Results:We found that MPH was prescribed in 23 (29.1%) children and adolescents. Of the 23 patients on MPH, 4 patients (17.4%) were on MPH monotherapy and 18 patients (78.3%) were using risperidone concomitantly. MPH was prescribed primarily for symptoms of hyperactivity and impulsivity in ASDs patients. The mean dosage of MPH was 26.2±11.1㎎g/day and mean duration of treatment was 31.9±28.7 months. Mean CGI-S score improved significantly from baseline to endpoint (from 5.4±0.6 to 4.1±0.9 ; p<.01). MPH was reported to be effective in 17 patients (17/23, 73.9%), and 10 patients (10/23, 43.5%) reported side effects. Side effects included decreased appetite (4/23, 17.4%), tic (2/23, 8.6%), sleep disturbances (2/23, 8.6%), headache (1/23, 4.3%) and irritability (1/23, 4.3%). Conclusion:The results of this study demonstrate that MPH may be used effectively and safely in children and adolescents with ASDs with hyperactivity and impulsivity. Future controlled trials are needed to confirm these findings.
백봉석(Bong Seok Baek),김길숙(Gil Sook Kim),진혜경(Hea Kyung Jhin),오동열(Dong Yul Oh),김경빈(Kyung Bin Kim) 한국중독정신의학회 2002 중독정신의학 Vol.6 No.2
Objective:The aim of this study was to evaluate the effect of an adolescent substance abuse treatment model with various measurements. Method:Twenty adolescent substance abusers referred by various agencies participated in structured treatment program during 8 weeks. Measurements used to evaluate the combined psychopathology were the Children’s Depression Inventory, State-Trait Anxiety Inventory for Children and Conner’s Scale. Measurements used to evaluate the treatment effect was Symptom Checklists (in Comprehensive Substance Treatment and Rehabilitation Questionnaire), Readiness to Change-drug, Herth Hope Index, Impulsivity Scale, and Satisfaction questionnaire (in CSTAR). Result:1) There were significant differences in CDI, SAIC, Conner’s Scale between patients and control group (thirty high school students). 2) There were significant changes in Symptom checklists, Readiness to Change-drug, Impulsivity scale. 3) There were positive responses in satisfaction questionnaire of treatment program except question about staff quality. Conclusion:These results suggest that multi-disciplinary structured treatment program is effective for adolescent substance abusers and multi-dimensional assessment of patients is inevitable to evaluate the change of patients.
Dibenzepine이 가토 혈중 주정농도에 미치는 영향에 관한 실험적 연구
진혜경 大韓神經精神醫學會 1980 신경정신의학 Vol.19 No.1
Dibenzepine is a new dibenzodizepine derivative with tricyclci chemical configuration. Chemically, it is 10-[2-(dimethylamino)ethyl]-5, 10-dihydro-5-methyl-11-H-dibenzo [b,e][1,4] diazepine-11-one Hydrochloride. In the clinical investigation, it was found to have moderate anxiolytic and thymoanaleptic action and to be safe drug. It has mild or transient side effect and good tolerance, even in larger dosage. It shows more rapid drug response, and is suitable to use in outpatient treatment. Many clinicial investigators have suggested that dibenzepine is indicated for depression of endogenous, endoreactive and reactive origin, involutional and organic depression. Also, investigators suggested that any new psychotropic drugs should be tested for its interaction with alcohol, because they might precipitate the risk situation in case of consuming them concurrently. In view of these reports, the author conducted an animal experiment to investigate the effects of dibenzepine on blood alcohol level in rabbits. Material and Method 1. The experimental work was done on mature rabbits of both sexes, weighing about 2 ㎏. 2. The experimental animals were divided into two group: the control anp the experimental group. 3. The control group was given alcohol alone. 4. The experimental group was divided into 4 subgroups: a) alcohol plus dibenzepine, 80㎎/㎏ of body weight daily for 5 days. b) alcohol plus dibenzepine, 80㎎/㎏ of body weight daily for 10 days. c) alcohol plus dibenzepine, 160㎎/㎏ of body weight daily for 5 days. d) alcohol plus dibenzepine, 160㎎/㎏ of body weight daily for 10 days. 5. Dibenzepine was given orally in a single dose at a fixed time. The last dose was given one hour and a half before alcohol administration. 6. In all groups, 20% ethanol solution was slowly given in a dose of 5.0㎖/㎏ of body weight for 5 minutes by intravenous route. 7. All of the blood specimens were obtained by cardiac puncture at both 15 and 45 minutes after alcohol administration 8. The determination of blood alcohol level was made by Cavett's method. Results 1. Alcohol plus dibenzepine, 80㎎/㎏ of body weight daily for 5 day. Dibenzepine did not change the blood alcohol level significantly at both 15 and 45 minutes after alcohol administration (p>0.05). 2. Alcohol plus dibenzepine, 80㎎/㎏ of body weight daily for 10 days. In this group, these was also no significant change in the blood level at both 15 and 45 minutes after alcohol administration (p>0.05). 3. Alcohol plus dibenzapine, 160㎎/㎏ of body weight daily for 5 days. In this group, these was also no significant change in the blood level at both 15 and 45 minutes after alcohol administration (p>0.05). 4. Alcohol plus dibenzapine, 160㎎/㎏ of body weight daily for 10 days. In this group, dibenzepine elevated the blood alcohol level significantly at both 15(p>0.02) and 45 (p 0.02) minutes after alcohol administration. Conclusion 1. Dibenzepine when administered orally in a dose of 80㎎/㎏ of body weight dialy for 5 or 10 days, did not change the blood alcohol level significantly at both 15 and 45 minutes after alcohol administration. 2. Dibenzepine, when administered orally in a dose of 160㎎/㎏ of body weight daily for 5 days, did not elevate the blood alcohol level significantly at both 15 and 45 minutes after alcohol administration. But, dibenzepine, when administered orally in the same dose daily for 10 days, elevated the blood alcohol level significantly at both 15 and 45 minutes after alcohol administration.